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Background: The objective of this study was to investigate the expression and clinical role of 14 genes previously
shown to be associated with chemotherapy response and/or progression-free survival in a smaller series of ovarian
serous carcinoma effusions.
Methods: Advanced-stage serous ovarian carcinoma effusions (n = 150) were analyzed for mRNA expression of
AKR1C1, ABCA4, ABCA13, ABCB10, BIRC6, CASP9, CIAPIN1, FAS, MGMT, MUTYH, POLH, SRC, TBRKB and XPA using
quantitative real-time PCR. mRNA expression was studied for association with clinicopathologic parameters, including
chemotherapy response and survival.
Results: ABCA4 mRNA expression was significantly related to better (complete) chemotherapy response at diagnosis in
the entire cohort (p = 0.018), whereas higher POLH mRNA levels were significantly related to better chemoresponse at
diagnosis in analysis to 58 patients with pre-chemotherapy effusions treated with standard chemotherapy (carboplatin +
paclitaxel; p = 0.023). In univariate survival analysis for patients with pre-chemotherapy effusions (n = 77), CIAPIN1 mRNA
expression was significantly related to shorter overall (p = 0.007) and progression-free (p = 0.038) survival, whereas
ABCA13 mRNA expression was significantly related to shorter OS (p = 0.024). Higher CIAPIN1 mRNA expression was
an independent marker of poor overall survival in Cox multivariate analysis (p = 0.044).
Conclusions: Our data identify ABCA4 and POLH as markers of better chemotherapy response in metastatic
serous carcinoma. CIAPIN1 and ABCA13 may be novel markers of poor outcome in pre-chemotherapy serous
carcinoma effusions.
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Ovarian cancer, consisting predominantly of ovarian car-
cinoma (OC), is the most lethal gynecologic malignancy,
constituting the 5th and 4th most common cause for
cancer-related death in women in the U.S. and Norway,
respectively [1,2]. Standard therapy consists of surgical
cytoreduction followed by adjuvant chemotherapy using
carboplatin and paclitaxel. While the majority of patients
will respond to chemotherapy, the majority of tumors
will recur within a median period of 18 months and be-
come chemoresistant, resulting in 5-year survival of 30%
for advanced-stage disease [3]. Mechanisms by which* Correspondence: bend@medisin.uio.no
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unless otherwise stated.cancer cells acquire resistance to platinum agents in-
clude reduced cellular uptake, increased efflux, increased
DNA repair and hypermethylation of MLH1, part of the
mismatch repair (MMR) system. Resistance to paclitaxel
occurs through overexpression of multi-drug resistance
protein 1 (MDR1), tubulin mutations and chromosomal
instability [4]. Our current understanding of the molecu-
lar events that mediate chemoresistance in recurrent
and metastatic OC is limited by the paucity of studies
focusing on extra-ovarian disease.
OC progresses predominantly within the abdominal cav-
ity and to a lesser degree by metastasis to the pleural
space, frequently with the formation of malignant effu-
sions. The serosal cavities are additionally a frequent site
of disease recurrence [5]. We previously analyzed 32 ser-
ous OC effusions for the expression of 381 genes which
have been reported to be associated with chemoresistancel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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were significantly associated with overall survival (OS),
progression-free survival (PFS) and/or chemotherapy re-
sponse [6]. In addition to its limited size, the latter study
analyzed together primary diagnosis pre-chemotherapy ef-
fusions and effusions obtained post-chemotherapy, pre-
dominantly at disease recurrence. The objective of the
present study was to analyze the expression of 14 genes
found to be associated with chemoresponse and/or PFS in
a larger cohort, consisting of 150 patients with serous OC
effusions.
Materials and methods
Patients and material
Fresh non-fixed malignant peritoneal (n = 125) and
pleural (n = 25; total = 150) effusions were obtained from
150 patients with FIGO stage III or IV serous ovarian,
peritoneal or tubal carcinoma treated at the Department
of Gynecologic Oncology at the Norwegian Radium
Hospital in the period 1998–2008. Due to their closely-
linked histogenesis and phenotype, all are referred to as
OC henceforth. Informed consent was obtained accord-
ing to national guidelines. The study was approved by
the Regional Committee for Medical Research Ethics in
Norway. Clinicopathologic data are detailed in Table 1.Table 1 Clinicopathologic parameters of the study cohort
(150 patients)
Parameter Number of patients
Age 35-87 years (mean = 62)
Histological grade Low 3
High 120
NAa 27
FIGO stage III 83
IV 67
Residual disease ≤1 cm 59
>1 cm 63
NAb 28
CA 125 at diagnosisc 11-43800 years (mean = 3375)
Chemoresponse after
primary treatmentd
CR 78
PR 32
SD 9
PD 21
NE 10
aNA = non available, including effusions from inoperable patients where biopsy
was too small for grading or patients operated on in other hospitals, for which
the primary tumor could not be accessed for assessment of grade.
bNA = non available, including 4 patients who only received chemotherapy
and 1 patient who received no therapy.
cCA 125 levels available for 104 patients.
dCR = complete response, PR = partial response, SD = stable disease,
PD = progressive disease, NE = disease response after chemotherapy could
not be evaluated because of adverse effects, normalized CA-125 after
primary surgery or missing CA-125 information and no residual tumor.Eighty-six patients had primary surgery, 56 had sec-
ondary debulking and 4 patients only received chemo-
therapy. One patient received no therapy, and 3 patients
referred at disease recurrence had no data available re-
garding therapy at diagnosis. Seventy-seven samples
were obtained prior to chemotherapy administration,
and 69 were obtained after chemotherapy, at interval
debulking surgery or at recurrent disease. Chemotherapy
status was unknown in 4 cases. The majority of patients
(n = 138) received platinum-based therapy, of whom 101
received platinum + paclitaxel, 27 received single carbo-
platin and 10 received platinum combination. Of the
remaining 12 patients, 10 received other chemotherapy
and 1 received no therapy, whereas no information was
available for 1 patient.
Effusions were submitted for routine diagnostic pur-
poses and were processed immediately after tapping.
Cell blocks were prepared using the Thrombin clot
method. Diagnoses were established using morphology
and immunohistochemistry (IHC). Effusion specimens
were centrifuged immediately after tapping, and cell pel-
lets were frozen at −70°C in equal amounts of RPMI
1640 medium (GIBCO-Invitrogen, Carlsbad CA) con-
taining 50% fetal calf serum (PAA Laboratories GmbH,
Pasching, Austria) and 20% dimethylsulfoxide (Merck
KGaA, Darmstadt, Germany). Smears and H&E-stained
cell block sections were reviewed by a surgical patholo-
gist experienced in cytopathology (BD). The tumor cell
population was >50% in all specimens.
Quantitative real-time PCR (qRT-PCR)
Effusions were centrifuged to obtain a cell pellet from
which RNA was extracted using QIAsymphony (Qiagen,
Hilden Germany). Details regarding reverse transcrip-
tion, primer and probe design procedure and software,
and efficiency testing were recently described [7]. The
qRT-PCR reaction was run using the Perfecta qPCR
ToughMix (Quanta Biosciences, Gaithersburg MD) and
quantified on the Roche LightCycler 480 (Roche, Basel,
Switzerland). Samples were analyzed in triplicate and
average copy number was used for statistical analysis.
Primer and probe sequences are detailed in Table 2.
The beta-glucuronidase (GUS), TATA box binding pro-
tein (TBP) and mitochondrial ribosomal protein L19
(MRLP19) genes were used as reference genes following
previous testing [7] applying established guidelines [8-10].
Primer and probe sequences were previously detailed [7].
IHC
Formalin-fixed paraffin-embedded sections from 109 of
the 150 effusions analyzed using qRT-PCR were analyzed
for Ciapin1 protein expression using the Dako EnVision™
Flex + System (K8012; Dako, Glostrup, Denmark). Depar-
affinization and unmasking of epitopes were carried out in
Table 2 Primers and probes
Gene Sequence
ABCA4 F-ACTTCTTCAAGCTCTTCCGTGTGC
NM_000350.2 R-TCAGATAATATTCCTCCCCAAGATCTCAG
EXON 6-7 P-CCACACTCCTAGACAGCCGTTCTCAAGGTATC
ABCA13 F-CTGTGGAAGAATTGGCTCTGCA
NM_152701.3 R-CAGAATTACAAACAGGATACAAGGCCAG
EXON 1-2 P-CTCAGGAACCCGGTCCTTTTCCTTGCTGAATTC
BIRC6 F-CACGTCCAGAACTCGGAGTG
NM_016252.3 R-AGGTAAATGTCTCCCGTCTGTTAGC
EXON 4-5 P-AGGCCGTTCTGTAGACAGATCACTGATGTATAGTG
CASP9 F-CAGACCAGTGGACATTGGTTCTG
NM_001229.3 R-CTCAGGATGTAAGCCAAATCTGCAT
EKSON 3-4 P-TGGTGATGTCGGTGCTCTTGAGAGTTTGAG
CIAPIN1 F-CACCAAGAAGTCTTCTCCTTCAGTG
NM_020313.2 R-GCTGAGAGGGTCCACAGCT
EXON 5-6 P-ACCTGCTGTGGACCCTGCTGCTG
MGMT F-CATCCCGTTTTCCAGCAAGAG
NM_002412.3 R-GGTAAGAAATCACTTCTCCGAATTTCA
EXON 3-4 P-TTCACCAGACAGGTGTTATGGAAGCTGCTGAAG
TPRKB F-GGGAGCTCTTCCGAGACG
NM_016058.2 R-GTCCAGCTGATGTGTTAACTGCAT
EXON 1-2 P-TGGGGGCCGGATGTAGAATCCTGCTTA
XPA F-CACAATGGGGTGATATGAAACTCTACT
NM_000380.3 R-CCTTTGCTTCTTCTAATGCTTCTTGACT
EXON 4-5 P-AAGTTACAGATTGTGAAGAGGTCTCTTGAAGTTTGGG
POLH F-TATGTCCAGATCTTCTACTGGCACAAGT
NM_006502.2 R-AAAACGAGACATTATCTCCATCACTTCA
EXON 3-4 P-CGTGGGAAAGCTAACCTCACCAAGTACCGG
FAS F-GATTGCTCAACAACCATGCTG
NM_000043.4 R-GGGCATTAACACTTTTGGACGAT
EXON 1-2 P-TGGACCCTCCTACCTCTGGTTCTTACGTCTGTTGCTAG
SRC F-CCCCTGCCTTCTACCAGGAC
NM_005417.3 R-CGGCGGGCTCCAGGCT
EXON 3-4 P-TGGGTAGCAACAAGAGCAAGCCCAAGGATG
AKR1C1 F-CATCAGACAGAACGTGCAGGTG
NM_001353.5 R-CAAAAATATCAAGGGTCAAATATCGC
EXON 7-8 P-CCAGTTGACTTCAGAGGAGATGAAAGCCATAGATG
MUTYH F-TCCACCGCCATGAAAAAGGT
NM_001048171.1 R-GACCTTTTGGAACCCATACAGGTC
EXON 14-15 P-TCCGTGTGTATCAGGGCCAACAGCCA
ABCB10 F-ACTCTCTTCCTTCCTAATGTATGCTTTCTG
NM_012089.2 R-CACCCAGTCCTTTCATCAGCT
EXON 6-4 P-TGGAATAAGCATTGGAGGTCTGAGCTCTTTCTACTC
F = Forward primer; R = Reverse primer; P = Probe. Probes are labeled with 5′
Fam and 3′non fluorescent quencher.
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solution at a low pH (Tris/EDTA pH 6). Sections were in-
cubated with a 0.3% hydrogen peroxide (H2O2) solution
for 5 min to block endogeneous tissue peroxidase activity.
Sections were incubated with a rabbit polyclonal Ciapin1
antibody (NBP1-89097, Novus Biologicals, Littleton, CO;
1:100 dilution), and then treated with EnVision™ Flex +
mouse linker (15 min) and EnVision™ Flex/HRP enzyme
(30 min). Sections were stained for 10 min with 3’3-diami-
nobenzidine tetrahydrochloride (DAB), counterstained
with hematoxylin, dehydrated and mounted in Richard-
Allan Scientific Cyto seal XYL (Thermo Fisher Scientific,
Waltham, MA). Positive and negative controls consisted
of bladder carcinoma and sections stained with rabbit
serum, respectively.
Interpretation
Staining was considered positive when localized to the
cytoplasm or nucleus. Staining extent was scored on a
scale of 0–4, corresponding to staining of 0%, 1-5%, 6-
25%, 26-75% and 76-100% of cells. No specimen contained
less than 100 tumor cells. Slides were scored by a surgical
pathologist experienced in effusion cytology (BD).
Statistical analysis
Statistical analysis was performed applying the SPSS-PC
package (Version 18, Chicago IL). Probability of <0.05 was
considered statistically significant. Analysis of the associ-
ation between mRNA levels of the 14 studied genes, as
well as Ciapin1 protein expression, and clinicopathologic
parameters was performed using the Mann–Whitney U
test. For this analysis, as well as for survival analysis, clini-
copathologic parameters were grouped as follows: Age:
≤60 vs. >60 years; effusion site: peritoneal vs. pleural;
FIGO stage: III vs. IV; chemotherapy status: pre- vs. post-
chemotherapy specimens; Residual disease (RD): ≤1 cm
vs. >1 cm; chemotherapy response: complete vs. partial re-
sponse/stable disease/progression; primary (intrinsic) che-
moresistance: PFS ≤6 months vs. >6 months. Histological
grade was not used for statistical analyses due to the small
number of low-grade tumors. The paired-sample T-test
was used to analyze the association between mRNA ex-
pression levels of the studied genes and CA 125 levels.
PFS and OS were calculated from the date of the last
chemotherapy treatment/diagnosis to the date of
recurrence/death or last follow-up, respectively. Uni-
variate survival analyses of PFS and OS were executed
using the Kaplan-Meier method and log-rank test.
Platinum resistance was defined as PFS ≤ 6 months ac-
cording to guidelines published by the Gynecologic
Oncology Group (GOG) [11] and progressive disease
or recurrence was evaluated by the RECIST criteria
[12]. Multivariate analysis was performed using the
Cox Regression Model (Enter function).
Table 4 Significant associations between gene expression
in pre-chemotherapy effusions and clinicopathologic
parameters (77 patients)
Parameter Gene Overexpression P-value
Anatomic site FAS Pleura p = 0.034
Age ABCB10 Age >60 years p = 0.005
FIGO stage MUYTH III p = 0.03
ABCA4 III p = 0.011
Residual disease MGMT ≤1 cm p = 0.007
TBRKB ≤1 cm p = 0.003
ABCB10 ≤1 cm p = 0.014
CA 125 levels at diagnosis ABCA4 Positive association p = 0.003
ABCB10 Negative association p = 0.042
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Chemoresistance-associated genes are significantly
related to clinicopathologic parameters
Analysis of mRNA levels for the 14 studied genes in the
150 effusions identified several significant associations
with anatomic site, patient age and residual disease vol-
ume (Table 3). No significant associations were found
with chemotherapy status (pre- vs. post-chemotherapy
specimens) or with FIGO stage (p > 0.05).
Our previous research has demonstrated that pre- and
post-chemotherapy effusions differ considerably with re-
spect to expression of cancer-associated molecules and
their clinical relevance [5]. Despite the absence of signifi-
cant differences in expression of the 14 studied genes
among pre- and post-chemotherapy effusions, we there-
fore analyzed them separately.
Significant associations for pre-chemotherapy cases
are shown in Table 4. In analysis of post-chemotherapy
effusions, only age was significantly associated with gene
expression, with associations identified between older age
and lower ABCA4 (p = 0.02) and higher BIRC6 (p = 0.03),
ABCA13 (p = 0.008) and FAS (p = 0.018) levels.
Ciapin1 protein was expressed in the cytoplasm of OC
cells in 92/109 effusions, of which 28 had score = 1, 25
score = 2, 24 score = 3 and 15 score = 4 (Figure 1).
Nuclear localization was observed in <10 cases and was
not scored (Figure 1). Expression in reactive mesothelial
cells was observed in 2 cases, while staining was tumor-
specific in the remaining effusions.
ABCA4 and POLH mRNA expression is related to complete
chemotherapy response at diagnosis
In analysis of the 144 patients which had data regarding
chemotherapy response at diagnosis, higher ABCA4
mRNA expression was significantly related to betterTable 3 Significant associations between gene expression
and clinicopathologic parameters in the entire study
cohort (150 patients)
Parameter Gene Overexpression P-value
Anatomic site ABCA13 Peritoneum p = 0.03
FAS Pleura p = 0.041
Age ABCB10 Age >60 years p = 0.006
BIRC6 Age >60 years p = 0.004
ABCA13 Age >60 years p = 0.011
CASP9 Age >60 years p = 0.049
Residual disease XPA ≤1 cm p = 0.046
MGMT ≤1 cm p = 0.04
TBRKB ≤1 cm p = 0.002
ABCB10 ≤1 cm p = 0.011
CA 125 levels at diagnosis ABCA4 Positive association p = 0.011
ABCB10 Negative association p = 0.01(complete) chemoresponse at diagnosis (p = 0.018). In
evaluation of the relationship between gene expression
and primary chemoresistance in the entire cohort, no
significant associations were found (p > 0.05). However,
trends for association between high ABCA13 (p = 0.059)
and low FAS (p = 0.053) mRNA levels with primary che-
moresistance were observed.
In analysis of the 73 patients with pre-chemotherapy
effusions which had data regarding chemotherapy re-
sponse at diagnosis, higher CIAPIN1 mRNA expression
was associated with a trend for worse (non-complete)
chemoresponse at diagnosis (p = 0.052). A trend was
additionally found between low FAS mRNA levels and
primary chemoresistance (p = 0.056).
Limiting the analysis to 58 patients with pre-
chemotherapy effusions treated with standard chemotherapy
(carboplatin + paclitaxel) identified POLH mRNA as marker
better chemoresponse at diagnosis (p = 0.023). Ciapin1 pro-
tein expression was unrelated to chemotherapy response.
CA 125 level at diagnosis, available for 59 patients with
pre-chemotherapy effusions, was not significantly related
to chemoresponse at diagnosis (p = 0.207). HE4, which is
currently measured in all OC patients at our hospital, was
not measured in the period the effusions studied in this
series were collected (1998–2008), and therefore cannot
be assessed for performance in this study.
None of the studied genes was related to chemoreponse
at diagnosis or to primary chemoresistance in the group of
patients with post-chemotherapy effusions (p > 0.05).CIAPIN1 and ABCA13 are prognostic markers in
pre-chemotherapy serous OC effusions
The follow-up period for the 150 patients ranged from 1
to 156 months (mean = 33 months, median = 24 months).
PFS, available for 149 patients, ranged from 0 to
116 months (mean = 9 months, median = 5 months). At
the last follow-up, 1 patient was alive with no evidence
Figure 1 Ciapin1 protein expression by immunohistochemistry. (A-B) Diffuse Ciapin1 expression (>75% of tumor cells) in the cytoplasm of
OC cells in 2 effusions; (C) Focal expression (<5%) in another specimen; (D) Nuclear localization of Ciapin1, an unusual finding in this series.
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of disease. One patient died of unrelated causes.
In survival analysis for all patients, none of the studied
genes was significantly related to OS or PFS. The same
findings were observed for the patient group with post-
chemotherapy effusions. However, in univariate survival
analysis for patients with pre-chemotherapy effusions
(n = 77), CIAPIN1 mRNA expression was significantly
related to shorter OS (p = 0.007; Figure 2-A) and PFS
(p = 0.038; Figure 2-B). In addition, ABCA13 mRNA ex-
pression was significantly related to shorter OS (p = 0.024;
Figure 2-C), though not with PFS (p = 0.192). ABCA4 and
POLH expression was not significantly related to survival,
and the same was true for Ciapin1 protein expression.
Among the clinical parameters, older age was signifi-
cantly related to shorter OS (p = 0.044) and was associated
with a trend for poor PFS (p = 0.055). RD volume >1 cm
was significantly related to poor PFS (p = 0.031), with non-
significant association with OS (p = 0.196). CA 125 level at
diagnosis in patients with pre-chemotherapy effusions
were unrelated to PFS (p = 0.185) or to OS (p = 0.413)
in this patient group.
The parameters entered into Cox analysis of OS and
PFS were all those with p < 0.2, i.e. CIAPIN1 and ABCA13
mRNA expression, RD volume and age for both
endpoints. In Cox multivariate analysis of OS, higherCIAPIN1 mRNA expression was the only independent
marker of poor outcome (p = 0.044). In Cox multivariate
analysis of PFS, larger RD was the sole independent
marker (p = 0.041).
In univariate survival analysis for patients with pre-
chemotherapy effusions who received combination
chemotherapy with carboplatin and paclitaxel (n = 58),
ABCA13 mRNA expression (p = 0.006) and older age
(p = 0.026) were significantly related to shorter OS.
Non-significant associations with shorter OS were ob-
served for CIAPIN1 mRNA expression (p = 0.146) and RD
volume (p = 0.141). In Cox multivariate analysis, none of
these markers was an independent prognosticator.
Discussion
Intrinsic and acquired drug resistance remains a major
therapeutic obstacle in OC [3], and our understanding
of the cellular mediators of this phenomenon in meta-
static OC cells is limited by the paucity of large series of
such specimens. In the present study we assessed the
predictive and prognostic role of 14 genes identified as
potentially clinically relevant in an earlier study [6]. Our
data only partially confirm the initial report. Inconsistent
results from different mRNA expression studies are not
infrequent and different methodology is the major cause
of these discrepancies [13]. In our case the initial study
Figure 2 CIAPIN1 and ABCA13 mRNA expression is associated
with shorter survival in serous ovarian carcinoma. A: Kaplan-Meier
survival curve showing the association between CIAPIN1 mRNA
expression in effusions and overall survival (OS) for patients with
pre-chemotherapy primary diagnosis effusions (n = 77). Patients
with effusions with higher-than-median expression (n = 36, dashed
line) had a mean OS of 22 months vs. 40 months for patients
whose effusions showed lower-than-median expression (n = 41,
solid line; p = 0.007). B: Kaplan-Meier survival curve showing the
association between CIAPIN1 mRNA expression in effusions and
progression-free survival (PFS) for patients with pre-chemotherapy
primary diagnosis effusions (n = 77). Patients with effusions with
higher-than-median expression (n = 36, dashed line) had a mean
PFS of 7 months vs. 11 months for patients whose effusions
showed lower-than-median expression (n = 41, solid line; p = 0.038).
C: Kaplan-Meier survival curve showing the association between
ABCA13 mRNA expression in effusions and OS for patients with
pre-chemotherapy primary diagnosis effusions (n = 77). Patients with
effusions with higher-than-median expression (n = 36, dashed line) had
a mean OS of 24 months vs. 39 months for patients whose effusions
showed lower-than-median expression (n = 41, solid line; p = 0.024).
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our in-house assay in which primers were designed by
our group and the average of 3 reference genes previ-
ously shown to be optimal for OC analysis was used for
normalization. The number of samples also differed con-
siderably, being 32 in the previous study vs. 150 in the
present one. Some findings were nevertheless repro-
duced, as CIAPIN1 and ABCA13 expression had prog-
nostic value in pre-chemotherapy patients and ABCA4
and POLH were predictive for complete chemotherapy
response at diagnosis. Additional correlation with clino-
pathologic parameters was found for anatomic site
(ABCA13 and FAS), patient age (ABCB10, BIRC6,
ABCA13 and CASP9) and residual disease volume (XPA,
MGMT, TBRKB and ABCB10). Though no association
was observed between gene levels and previous chemo-
therapy or FIGO stage in analysis of the entire cohort,
FIGO stage was significantly associated with MUTYH
and ABCA4 expression in pre-chemotherapy disease.
Three members of the ATP binding cassette (ABC)
family were assessed on the present study. These trans-
membrane proteins serve as efflux pumps and members
like MDR1 play a major role in multidrug chemoresis-
tance [14,15]. The role of ABCA4 in cancer is largely
unknown to date, whereas ABCB10 was previously
shown to be expressed in drug-resistant HT-29 colon
carcinoma cells [16]. Higher ABCA13 levels by qPCR
have been associated with better response to neoadju-
vant chemotherapy in breast cancer [17] and with longer
disease-free survival following chemotherapy in colorec-
tal cancer [18], and this gene was previously reported to
be underexpressed in renal cell carcinoma compared to
normal tissue [19]. Our data associate ABCA4 with bet-
ter chemotherapy response at diagnosis. However, the
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primary chemoresistance and the significant association
with poor OS suggest that this molecule may have a dif-
ferent role in serous OC.
The present study identified CIAPIN1 as an independ-
ent prognostic marker of poor outcome for patients with
pre-chemotherapy effusions. Cytokine induced apoptosis
inhibitor 1 (CIAPIN1) is an anti-apoptotic protein exert-
ing its function through post-translational modifications
of cell cycle proteins including p27, cyclins D1 and E
and the cyclin-dependent kinases CDK2 and CDK4. It
additionally cooperates with other proteins, such as
thioredoxin-like protein 2 (TXNL2), to inhibit apoptosis
via the mitochondrial (intrinsic) pathway. Ciapin1 add-
itionally regulates cell differentiation, organ development
and cellular stress response [20]. Nuclear expression of
CIAPIN1 was reported to be associated with poor prog-
nosis in a study of 108 primary OC [21]. In our series,
this protein was predominantly localized to the cyto-
plasm, nuclear expression being too infrequent to be
considered of clinical relevance. This emphasizes the dif-
ferences between primary OC and effusion specimens,
but may also reflect the fact that the study by Cai et al.
included both serous and non-serous tumors, whereas
our series consisted uniformly of the former.
POLH, encoding Polymerase η, was associated with
complete response to primary chemotherapy in the pa-
tient group with pre-chemotherapy effusions treated
with standard chemotherapy (carboplatin + paclitaxel).
POLH, a.k.a. XPV and RAD30A, is member of the Y-
family of DNA polymerases. Mutation in this protein is
the basis for the Variable type of Xeroderma Pigmento-
sum, a genetic disease with impaired DNA repair associ-
ated with skin cancer [22]. Polymerase η was further
reported to mediate resistance to cisplatin by extending
primers after DNA cross-linking induced by the drug
[23]. Our data do not support this role and rather con-
stitute the first report attributing a potential beneficial
clinical role to this molecule in OC.
The remaining genes analyzed in this study were not
informative for chemotherapy response or survival. Pro-
tein expression of FAS, activator of the extrinsic apop-
tosis pathway, by flow cytometry in OC effusions was
previously reported to be a marker for aggressive clinical
behavior by our group [24], but its mRNA was signifi-
cantly related only to anatomic localization (pleura vs.
peritoneum) in the present study. Similarly, protein ex-
pression of the DNA repair gene XPA was previously
found to be associated with better prognosis by our
group [25], whereas XPA mRNA expression was unre-
lated to survival in the present study. These discrepan-
cies likely reflect different methodology, as well as the
fact that protein and mRNA expression do not fully
overlap in many cases.The inhibitor of apoptosis (IAP) family consists of 8
proteins which are key regulators of apoptosis. IAP
members are overexpressed in many cancers and are
under considerable attention as therapeutic targets
[26,27]. Protein expression of the IAP member Apollon
(a.k.a. Baculoviral IAP Repeat Containing 6; BIRC6) in
primary OC was recently reported to be related to poor
prognosis [28], an association which was not reproduced
in our analysis of BIRC6 mRNA levels in effusions. Simi-
larly, SRC, modulator of response to paclitaxel and a po-
tential molecular target in OC [29], was not informative
of therapy response or survival in our series.
TPRKB, a.k.a. TP53RK, binds and activates p53 by
phosphorylation. The gene is located in the 20q13.12-13
region which is amplified in OC and was reported to be
associated with primary chemoresistance [30]. TP53RK
silencing activates caspases 3 and 7 and sensitizes OC
cells to paclitaxel [31].
MUTYH is a DNA glycosylase that repairs oxidative
damage by replacing an incorrectly placed A with C,
thereby preventing mutations. However, it appears to
have additional roles, primarily as pro- and anti-
apoptotic marker, and is localized to both the mitochon-
dria and the nucleus. MUTYH is implicated in cancer,
inflammation and Parkinson disease. Mutations in
MUTYH predispose individuals to colorectal cancer
[32], as well as increased risk of developing OC [33].
O-6-methylguanine-DNA methyltransferase (MGMT),
an enzyme regulated primarily through promoter methy-
lation, repairs DNA damage caused by alkylating lesions
and thus rescues tumor cells from apoptosis [34]. Higher
MGMT activity was reported to be associated with cis-
platin resistance in OC [35].
AKR1C1 is family member of the Aldo-keto reduc-
tases, and have been reported to enhance progesterone
metabolism in ovarian endometriosis [36].
A relevant question concerning the results of the
present study would be how other biomarkers perform
in this cohort with respect to predicting chemotherapy
response or as prognostic factors. We recently published
a retrospective analysis of 143 serous OC effusions in
which we assessed the clinical role of 41 previously stud-
ied proteins. In this series, several proteins that were
significantly related to chemotherapy response and/or
survival (the latter in pre-chemotherapy effusions) were
identified, including survivin, fatty acid synthase (FAS),
p21-activated kinase-1 (PAK1), osteopontin, peroxisome
proliferator-activated receptor-γ (PPARγ), S100A4, Bcl-
XL, high-mobility group protein A2 (HMGA2), NAC-1,
signal transducer and activator of transcription 5B
(STAT5B) and heat shock protein 90 (HSP90) [37].
Analysis of the clinical role of these markers in the pre-
chemotherapy specimens analyzed in the present study
identified only nuclear survivin expression as significantly
Nymoen et al. Molecular Cancer  (2015) 14:44 Page 8 of 9related to chemotherapy response (favorable; p = 0.017) or
OS (favorable; p = 0.013). It should nevertheless be com-
mented that the number of overlapping specimens was 47
or less for these markers. We are currently performing a
similar multivariate analysis for biomarkers studied at the
mRNA level, which may complement the current study in
identifying clinically relevant targets in OC effusions.
In conclusion, analysis of 14 chemoresistance-associated
genes in a large series of serous OC effusions identified
CIAPIN1, ABCA4, ABCA13 and POLH as potential
markers of survival or chemotherapy response in this set-
ting, findings which merit in our opinion further research.
Multiple associations were additionally identified between
the studied genes and various clinicopathologic parame-
ters. While some of the latter may represent errors of mul-
tiple testing, the stronger associations (p < 0.005) may
represent true findings. Sorting the clinically relevant from
the non-relevant molecular markers in recurrent and/or
metastatic OC may aid in selection of therapeutic targets
in this cancer.
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